Baidu
map

FDA批准用于HIV/AIDS患者抗腹泻药

2013-01-06 FDA CMT 晓静 编译

    2012年12月31日,美国食品与药物管理局(FDA)批准了Fulyzaq(crofelemer)用以减轻接受抗逆转录病毒联合治疗的HIV / AIDS患者腹泻症状。该药是植物处方药,其活性成分来自龙血巴豆(Croton lechleri)汁液。   许多患者停止或转换抗逆转录病毒药物治疗是因为腹泻的原因。Fulyzaq预期用于治疗非

HIV
 

  2012年12月31日,美国食品与药物管理局(FDA)批准了Fulyzaq(crofelemer)用以减轻接受抗逆转录病毒联合治疗的HIV / AIDS患者腹泻症状。该药是植物处方药,其活性成分来自龙血巴豆(Croton lechleri)汁液。

  许多患者停止或转换抗逆转录病毒药物治疗是因为腹泻的原因。Fulyzaq预期用于治疗非病毒、细菌或病毒感染引起的HIV / AIDS腹泻患者。治疗水样泻Fulyzaq每日应用两次。

  临床试验中观察到的最常见不良反应为上呼吸道感染,支气管炎,咳嗽,胃胀和肝酶胆红素水平升高。

  Fulyzaq是第二个FDA批准的植物处方药。Veregen(sinecatechins)为首个FDA批准的植物处方药,于2006年获准,是一种肛门和生殖器周围疣的局部治疗药物。

  英文链接:FDA approves first anti-diarrheal drug for HIV/AIDS patients



    

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2033798, encodeId=00582033e98a7, content=<a href='/topic/show?id=852b216824' target=_blank style='color:#2F92EE;'>#AID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2168, encryptionId=852b216824, topicName=AID)], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=1072181, createdName=wjywjy, createdTime=Thu Jun 13 22:18:00 CST 2013, time=2013-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2042095, encodeId=7455204209544, content=<a href='/topic/show?id=b0db88910c' target=_blank style='color:#2F92EE;'>#HIV/AIDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8891, encryptionId=b0db88910c, topicName=HIV/AIDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Sun Dec 01 14:18:00 CST 2013, time=2013-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839210, encodeId=639e1839210a8, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Fri Sep 06 20:18:00 CST 2013, time=2013-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365594, encodeId=e6831365594f1, content=<a href='/topic/show?id=41fa21e036' target=_blank style='color:#2F92EE;'>#AIDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2170, encryptionId=41fa21e036, topicName=AIDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Jan 08 04:18:00 CST 2013, time=2013-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489396, encodeId=a0d614893966c, content=<a href='/topic/show?id=6647650e22d' target=_blank style='color:#2F92EE;'>#泻药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65072, encryptionId=6647650e22d, topicName=泻药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Tue Jan 08 04:18:00 CST 2013, time=2013-01-08, status=1, ipAttribution=)]
    2013-06-13 wjywjy
  2. [GetPortalCommentsPageByObjectIdResponse(id=2033798, encodeId=00582033e98a7, content=<a href='/topic/show?id=852b216824' target=_blank style='color:#2F92EE;'>#AID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2168, encryptionId=852b216824, topicName=AID)], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=1072181, createdName=wjywjy, createdTime=Thu Jun 13 22:18:00 CST 2013, time=2013-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2042095, encodeId=7455204209544, content=<a href='/topic/show?id=b0db88910c' target=_blank style='color:#2F92EE;'>#HIV/AIDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8891, encryptionId=b0db88910c, topicName=HIV/AIDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Sun Dec 01 14:18:00 CST 2013, time=2013-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839210, encodeId=639e1839210a8, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Fri Sep 06 20:18:00 CST 2013, time=2013-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365594, encodeId=e6831365594f1, content=<a href='/topic/show?id=41fa21e036' target=_blank style='color:#2F92EE;'>#AIDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2170, encryptionId=41fa21e036, topicName=AIDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Jan 08 04:18:00 CST 2013, time=2013-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489396, encodeId=a0d614893966c, content=<a href='/topic/show?id=6647650e22d' target=_blank style='color:#2F92EE;'>#泻药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65072, encryptionId=6647650e22d, topicName=泻药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Tue Jan 08 04:18:00 CST 2013, time=2013-01-08, status=1, ipAttribution=)]
    2013-12-01 xuyu
  3. [GetPortalCommentsPageByObjectIdResponse(id=2033798, encodeId=00582033e98a7, content=<a href='/topic/show?id=852b216824' target=_blank style='color:#2F92EE;'>#AID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2168, encryptionId=852b216824, topicName=AID)], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=1072181, createdName=wjywjy, createdTime=Thu Jun 13 22:18:00 CST 2013, time=2013-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2042095, encodeId=7455204209544, content=<a href='/topic/show?id=b0db88910c' target=_blank style='color:#2F92EE;'>#HIV/AIDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8891, encryptionId=b0db88910c, topicName=HIV/AIDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Sun Dec 01 14:18:00 CST 2013, time=2013-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839210, encodeId=639e1839210a8, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Fri Sep 06 20:18:00 CST 2013, time=2013-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365594, encodeId=e6831365594f1, content=<a href='/topic/show?id=41fa21e036' target=_blank style='color:#2F92EE;'>#AIDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2170, encryptionId=41fa21e036, topicName=AIDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Jan 08 04:18:00 CST 2013, time=2013-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489396, encodeId=a0d614893966c, content=<a href='/topic/show?id=6647650e22d' target=_blank style='color:#2F92EE;'>#泻药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65072, encryptionId=6647650e22d, topicName=泻药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Tue Jan 08 04:18:00 CST 2013, time=2013-01-08, status=1, ipAttribution=)]
    2013-09-06 bugit
  4. [GetPortalCommentsPageByObjectIdResponse(id=2033798, encodeId=00582033e98a7, content=<a href='/topic/show?id=852b216824' target=_blank style='color:#2F92EE;'>#AID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2168, encryptionId=852b216824, topicName=AID)], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=1072181, createdName=wjywjy, createdTime=Thu Jun 13 22:18:00 CST 2013, time=2013-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2042095, encodeId=7455204209544, content=<a href='/topic/show?id=b0db88910c' target=_blank style='color:#2F92EE;'>#HIV/AIDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8891, encryptionId=b0db88910c, topicName=HIV/AIDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Sun Dec 01 14:18:00 CST 2013, time=2013-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839210, encodeId=639e1839210a8, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Fri Sep 06 20:18:00 CST 2013, time=2013-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365594, encodeId=e6831365594f1, content=<a href='/topic/show?id=41fa21e036' target=_blank style='color:#2F92EE;'>#AIDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2170, encryptionId=41fa21e036, topicName=AIDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Jan 08 04:18:00 CST 2013, time=2013-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489396, encodeId=a0d614893966c, content=<a href='/topic/show?id=6647650e22d' target=_blank style='color:#2F92EE;'>#泻药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65072, encryptionId=6647650e22d, topicName=泻药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Tue Jan 08 04:18:00 CST 2013, time=2013-01-08, status=1, ipAttribution=)]
    2013-01-08 智智灵药
  5. [GetPortalCommentsPageByObjectIdResponse(id=2033798, encodeId=00582033e98a7, content=<a href='/topic/show?id=852b216824' target=_blank style='color:#2F92EE;'>#AID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2168, encryptionId=852b216824, topicName=AID)], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=1072181, createdName=wjywjy, createdTime=Thu Jun 13 22:18:00 CST 2013, time=2013-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2042095, encodeId=7455204209544, content=<a href='/topic/show?id=b0db88910c' target=_blank style='color:#2F92EE;'>#HIV/AIDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8891, encryptionId=b0db88910c, topicName=HIV/AIDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Sun Dec 01 14:18:00 CST 2013, time=2013-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839210, encodeId=639e1839210a8, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Fri Sep 06 20:18:00 CST 2013, time=2013-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365594, encodeId=e6831365594f1, content=<a href='/topic/show?id=41fa21e036' target=_blank style='color:#2F92EE;'>#AIDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2170, encryptionId=41fa21e036, topicName=AIDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Jan 08 04:18:00 CST 2013, time=2013-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489396, encodeId=a0d614893966c, content=<a href='/topic/show?id=6647650e22d' target=_blank style='color:#2F92EE;'>#泻药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65072, encryptionId=6647650e22d, topicName=泻药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Tue Jan 08 04:18:00 CST 2013, time=2013-01-08, status=1, ipAttribution=)]

相关资讯

美国预防服务工作组HIV筛查推荐草案发布

  11月20日,美国预防服务工作组(USPSTF)在其网站发表一项推荐草案声明,强烈推荐所有年龄在15岁至65岁人群进行艾滋病病毒(HIV)筛查。声明还建议所有孕妇,以及处于HIV高危风险中的不到15岁的青少年和大于65岁的老年人进行HIV筛查。   专家组成员欧文斯指出,该推荐草案反映了筛查和早期治疗HIV益处的新证据。由于在感染艾滋病病毒的早期通常没有症状,人们需要经过筛查了解他们是否已被

CID:垂直感染HIV青少年心脏病负担重

  一项多国联合研究表明,垂直感染人类免疫缺陷病毒(HIV)的青少年心脏病负担显著。论文10月24日在线发表于《临床传染病》(Clin Infect Dis)杂志。   研究纳入110例垂直感染HIV的青少年(47%为男性,中位年龄15岁),评估病史、体格检查和多普勒超声心动图情况。   结果为,78例(71%)感染者接受抗逆转录病毒治疗(ART)。劳力性呼吸困难、胸痛、心

HIV患者的HCV感染可被安全治疗

  波士顿——约翰霍普金斯大学病毒性肝炎中心医学主管Mark Sulkowski博士在美国肝病研究学会(AASLD)年会上报告,接受选择性抗逆转录病毒药物+ telaprevir+peg干扰素+利巴韦林联合治疗的HIV/HCV共感染患者,具有较高水平的持续病毒学应答。Sulkowski博士强调,要想避免telaprevir(Incivek)与高活性抗逆转录病毒治疗(HAART)

国内HIV抗病毒治疗依从性预测模型建立

  近日,艾滋病患者刘某收到解放军第302医院护理人员发的一条手机短信:“刘大哥,您好!最近身体状况怎么样?别忘了按时吃药。常联系!”这是该院感染性疾病诊疗与研究中心根据建立的HIV感染者抗病毒治疗依从性预测模型评估出的结果,对刘某进行护理干预的一项内容。   据悉,该模型的建成填补了国内此类研究领域的空白,为医护人员有针对性地指导和干预患者抗病毒治疗提供了科学依据。   从2009年开始,3

我国加入HIV治愈全球计划

  12月16日从第二十四次中国科技论坛“HIV治愈高层论坛”上获悉,在卫生部支持下,我国已正式加入HIV治愈全球计划。   该计划中国负责人、中国疾病预防控制中心艾滋病首席专家邵一鸣介绍,在艾滋病治疗方面,基本问题已得到解决,艾滋病已从致死性疾病转为像乙肝这样可控制的慢性病。但艾滋病的治疗需终生服药,这种治疗方式让各国政府和患者背上了沉重的经济负担。如何终结艾滋病终生治疗模式,是国际艾滋病科研

JBC:艾滋病病毒包膜蛋白变异能逃避中和抗体VRC01的作用

随着对艾滋病研究的深入,研究人员已经发现了一些人体原本就存在的对付HIV非常有效的武器 尽管艾滋病的“元凶”——人类免疫缺陷病毒(HIV)狡猾多变,但“魔高一尺,道高一丈”——人体免疫系统有应对它攻击的一套办法。其实这些本领是与生俱来的,只是现在并没有被完全认识和挖掘出来。随着对艾滋病研究的深入,现在,研究人员已经从基因、免疫细胞和抗体等方面发现了一些人体原本就存在的对付HIV非常有效的武器

Baidu
map
Baidu
map
Baidu
map